A Phase II Study Of Perifosine (D-21266) In Previously Untreated Patients With Metastatic Or Recurrent Malignant Melanoma
- Determine the efficacy of perifosine, in terms of response rate, in previously
untreated patients with metastatic or recurrent malignant melanoma.
- Assess the toxicity of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral perifosine daily on days 1-21. Treatment repeats every 28 days for up
to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who
achieve a complete response (CR) or partial response (PR) receive 2 additional courses after
documentation of CR or stable PR (i.e., no further tumor shrinkage).
Patients are followed at 4 weeks and then every 3 months thereafter.
PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 12-18
Masking: Open Label, Primary Purpose: Treatment
Donald S. Ernst, MD, FRCPC
London Regional Cancer Program at London Health Sciences Centre
United States: Federal Government